Stock Research: AbbVie

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

AbbVie

NYSE:ABBV US00287Y1091
47
  • Value
    17
  • Growth
    73
  • Safety
    Safety
    53
  • Combined
    46
  • Sentiment
    61
  • 360° View
    360° View
    47
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

AbbVie Inc. is a global biopharmaceutical company focused on research, development, manufacturing, and commercialization of medicines and therapies. Key areas include Immunology, Oncology, Aesthetics, Neuroscience, and Eye Care. In the last fiscal year, the company had a market cap of $329,240 million, profits of $39,430 million, revenue of $56,334 million, and 55000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 47 (better than 47% compared with alternatives), overall professional sentiment and financial characteristics for the stock AbbVie are below the industry average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for AbbVie. The consolidated Value Rank has an attractive rank of 53, which means that the share price of AbbVie is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 53% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 73, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 61. But the company’s financing is risky with a Safety rank of 17. This means 83% of comparable companies have a safer financing structure than AbbVie. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
53 72 n/a n/a
Growth
73 35 n/a n/a
Safety
Safety
17 36 n/a n/a
Sentiment
61 96 n/a n/a
360° View
360° View
47 75 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
33 35 n/a n/a
Opinions Change
56 70 n/a n/a
Pro Holdings
n/a 94 n/a n/a
Market Pulse
64 85 n/a n/a
Sentiment
61 96 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
53 72 n/a n/a
Growth
73 35 n/a n/a
Safety Safety
17 36 n/a n/a
Combined
46 43 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
38 61 n/a n/a
Price vs. Earnings (P/E)
34 28 n/a n/a
Price vs. Book (P/B)
1 1 n/a n/a
Dividend Yield
90 100 n/a n/a
Value
53 72 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
57 35 n/a n/a
Profit Growth
58 53 n/a n/a
Capital Growth
76 33 n/a n/a
Stock Returns
55 59 n/a n/a
Growth
73 35 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
9 9 n/a n/a
Refinancing
7 5 n/a n/a
Liquidity
67 92 n/a n/a
Safety Safety
17 36 n/a n/a

Similar Stocks

Discover high‑ranked alternatives to AbbVie and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.